Intravitreal adalimumab for refractory uveitis-related macular edema.
Τίτλος | Intravitreal adalimumab for refractory uveitis-related macular edema. |
Publication Type | Journal Article |
Year of Publication | 2010 |
Authors | Androudi, S., Tsironi E., Kalogeropoulos C., Theodoridou A., & Brazitikos P. |
Journal | Ophthalmology |
Volume | 117 |
Issue | 8 |
Pagination | 1612-6 |
Date Published | 2010 Aug |
ISSN | 1549-4713 |
Λέξεις κλειδιά | Adult, Anti-Inflammatory Agents, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Female, Follow-Up Studies, Humans, Injections, Macular Edema, Male, Middle Aged, Prospective Studies, Retina, Retreatment, Tomography, Optical Coherence, Tumor Necrosis Factor-alpha, Uveitis, Visual Acuity, Vitreous Body, Young Adult |
Abstract | OBJECTIVE: To evaluate the safety and efficacy of intravitreal adalimumab injections on refractory cystoid macular edema (CME) secondary to noninfectious uveitis.DESIGN: Prospective, noncomparative, interventional case series.PARTICIPANTS: Eight consecutive patients with controlled uveitis and chronic, refractory CME who had failed steroid treatment.INTERVENTION: Intravitreal adalimumab injections were given monthly for 3 months.MAIN OUTCOME MEASURES: Mean change in central retinal thickness (CRT) on optical coherence tomography (OCT); secondary objective was the mean change in best-corrected visual acuity (BCVA).RESULTS: Five of the eight patients completed the 6-month follow-up. For all 5 patients, the changes in BCVA from baseline to 3 months were not statistically significant (P=0.070). Similarly, the change in BCVA from baseline to 6 months was not statistically significant (P=1.0). The mean CRT at baseline was 692 microm. The changes from baseline to 3 months were not statistically significant (P=0.466); the changes from baseline to 6 months were also not statistically significant (P=0.808). We did not observe any ocular or systemic adverse effects.CONCLUSIONS: Intravitreal adalimumab showed no efficacy in improving BCVA or reducing CRT in patients with chronic uveitic macular edema. |
DOI | 10.1016/j.ophtha.2009.12.011 |
Alternate Journal | Ophthalmology |
PubMed ID | 20378179 |